Therefore, these findings provide an additional evidence for the gastroprotective effects of rosiglitazone against IND-induced gastric ulceration, which could be mediated by its anti-inflammatory action via inhibition of inflammatory cytokines (e.g. TNF-α) production as well as inhibition of ROS production. This evidence concerns the gene TNF and gastric ulcer.